News From the Food and Drug Administration
March 16, 2021
A cell-based gene therapy to treat adults with large B-cell lymphoma (LBCL) has received FDA approval. Lisocabtagene maraleucel, marketed as Breyanzi, is a chimeric antigen receptor T-cell (CAR-T) therapy indicated for patients who haven’t responded to or have relapsed after at least 2 other systemic treatments.
Einen Kommentar schreiben
Sie müssen sich anmelden, um Kommentare hinzuzufügen.